VP
TPTX

venBio Partners’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

venBio Partners’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-160,333
Closed -$7.16M – 6
2020
Q1 		$7.16M Sell
160,333
-547,900
-77% -$29.1M 6.1% 4
2019
Q4 		$44.1M Sell
708,233
-632,032
-47% -$30.1M 18.91% 3
2019
Q3 		$50.4M Hold
1,340,265
– – 23.91% 2
2019
Q2 		$54.5M Buy
+1,340,265
New +$47.8M 24.21% 3

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

venBio Partners's TPTX Position: Q2 2020 in Review

venBio Partners sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2020, closing a stake of 160,333 shares — an estimated $7.16M sold.

venBio Partners first reported a position in TPTX in Q2 2019 and held it in 4 quarters. The position peaked at $54.5M in Q2 2019. 158 funds tracked by Wall St. Rank hold TPTX as of Q2 2020.

  • venBio Partners reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • venBio Partners sold 160,333 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $7.16M.
  • venBio Partners first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • venBio Partners's Turning Point Therapeutics, Inc. Common Stock position peaked at $54.5M in Q2 2019.
  • 158 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2020.

Based on venBio Partners's 13F filing for Q2 2020, filed 14 Aug 2020.